SARS-CoV-2 Safety Study for the Treatment of COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-28

Study Completion Date

2025-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection of G-quadruplex DNA Methylation in Cancer

NCT06537063

Cancer DNA G-quadruplex Methylation +1 more

WITHDRAWN

Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery

NCT03071913

Central Nervous System Neoplasm Localized Brain Neoplasm Metastatic Malignant Neoplasm in the Brain +1 more

COMPLETED

Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies

NCT04566614

Neoplasm, Colorectal Neoplasm of Lung Neoplasm, Bladder +3 more

COMPLETED

Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study

NCT04258137

Colorectal Cancer Non Small Cell Lung Cancer

RECRUITING NA

Protocols Development for Single Cells Genomics and Their Implementation for Molecular Diversity Between Cells

NCT02540941

Healthy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to change and disappear defective cells in virus variants, Covid-19 disease. Pluripotent stem cells produced strong cells serve as a repair system, replacing damaged cells, defective cells and dead cells.

CHEMISTRY:

SARS-CoV-2 does not use any chemicals, no colors and no additives and no preservatives.

Toxicology:

SARS-CoV-2 product is not adverse effect, non-toxic and no pharmacal toxicology.

SARS-CoV-2 is not placebo drug

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

SARS-CoV-2. Directions: For adults and for Children 1-12 years old. Indication: SARS-CoV-2.

Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Directions: For adults and for Children 1-12 years old. Indication: SARS-CoV-2 Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.

Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SARS-CoV-2 Safety Study for the Treatment of COVID-19

Directions: For adults and for Children 1-12 years old. Indication:SARS-CoV-2 Ingredients: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.

Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

Group Type EXPERIMENTAL

HIV

Intervention Type DRUG

Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.

Humidification: \<5% Dosage Form:

Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date

Malignant Neoplasms Safety Study for the Treatment of Neoplasms

Intervention Type DRUG

Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HIV

Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.

Humidification: \<5% Dosage Form:

Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date

Intervention Type DRUG

Malignant Neoplasms Safety Study for the Treatment of Neoplasms

Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.

Intervention Type DRUG